Table Info

Table 1.

The network optimization analogy

IT NetOps	Definition	Immune NetOps	Immune operators
Traffic shaping	Traffic shaping is a strategy to improve the performance and management of traffic in a network	JAK/STAT signaling pathway modulation	Immunosupressors
Data caching	Data caching is a process that stores multiple copies of data in a temporary storage location—or cache—so they can be accessed faster	Activation of trained immunity/innate immunity	BCG/influenza/pneumococcal vaccine
Data compression	Data compression is the process of encoding, restructuring data in order to reduce its size	Activation of adaptative immunity/immune memory	COVID-19 approved vaccines
Buffer tuning	Buffer tuning or network buffer, corresponds with the smallest unit for effective communication between subtasks	Concurrent activation of innate and adaptative immune responses/immune fitness	New type of vaccines/TIbV

BCG: bacillus Calmette-Guerin; TIbV: trained immunity-based vaccines

Declarations

Acknowledgments

The author fully acknowledges the intellectual assistance of CIINAS Corp.

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Barabási AL, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet. 2004;5:101–13. [DOI] [PubMed]

Yue X, Wang Z, Huang J, Parthasarathy S, Moosavinasab S, Huang Y, et al. Graph embedding on biomedical networks: methods, applications and evaluations. Bioinformatics. 2020;36:1241–51. [DOI] [PubMed] [PMC]

Koutrouli M, Karatzas E, Paez-Espino D, Pavlopoulos GA. A guide to conquer the biological network era using graph theory. Front Bioeng Biotechnol. 2020;8:34. [DOI] [PubMed] [PMC]

Bergthaler A, Menche J. The immune system as a social network. Nature Immunol. 2017;18:481–2. [DOI] [PubMed]

Decouttere C, Vandaele N, De Boeck K, Banzimana S. A systems-based framework for immunisation system design: six loops, three flows, two paradigms. Health Systems. 2021;[Epub ahead of print]. [DOI]

Banerjee A, Goswami RP, Chatterjee M. Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19. Sci Rep. 2021;11:2512. [DOI] [PubMed] [PMC]

Nguyen J, Yu W. Towards to inter-domain network operations for dynamic networks with software defined networking (SDN). EAI Endorsed Trans. 2019;4:e1. [DOI]

Klement RJ. Systems thinking about SARS-CoV-2. Front Public Health. 2020;8:585229. [DOI] [PubMed] [PMC]

Haraldsson HV. Introduction to systems thinking and causal loop diagrams. Reports in ecology and environmental engineering. Lund: Lund University; 2004.

10.

Luo W, Li YX, liang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmocol Sci. 2020;41:531–43. [DOI] [PubMed] [PMC]

11.

Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, et al. COVID-19 as a mediator of interferon deficiency and hyperinflammation: rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev. 2021;60:28–45. [DOI] [PubMed] [PMC]

12.

Buszko M, Nita-Lazar A, Park JH, Schwartzberg PL, Verthelyi D, Young HA, et al. Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol. 2021;22:404–11. [DOI] [PubMed] [PMC]

13.

Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;11:900–11. [DOI] [PubMed]

14.

Bouwman W, Verhaegh W, Holtzer L, van de Stolpe A. Measurement of cellular immune response to viral infection and vaccination. Front Immunol. 2020;11:575074. [DOI] [PubMed] [PMC]

15.

Frieman M, Heiseb M, Baric R. SARS coronavirus and innate immunity. Virus Res. 2008;133:101–12. [DOI] [PubMed] [PMC]

16.

Burgos-Salcedo J, Sierra C, Bunyard P. Systems immunology approach of within-host dynamics of coronavirus (SARS CoV-2) with innate immune response. J Health Sci Dev. 2021;4:5–11.

17.

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382:970–1. [DOI] [PubMed] [PMC]

18.

Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7. [DOI] [PubMed] [PMC]

19.

Bekkering S, Domínguez-Andrés J, Joosten LAB, Riksen NP, Netea MG. Trained immunity: reprogramming innate immunity in health and disease. Annu Rev Immunol. 2021;39:667–93. [DOI] [PubMed]

20.

Li J, Zhan L, Qin C. The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine. NPJ Vaccines. 2021;6:14. [DOI] [PubMed] [PMC]

21.

Goddeck S. Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate. Int J Infect Dis. 2020;99:286–90. [DOI] [PubMed] [PMC]

22.

Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front Immunol. 2018;9:2936. [DOI] [PubMed] [PMC]

23.

Burgos-Salcedo J. A rational strategy to support approved COVID-19 vaccines prioritization. Hum Vaccin Immunother. 2021;17:3474–7. [DOI] [PubMed] [PMC]

24.

Mayr A. Taking advantage of the positive side-effects of smallpox vaccination. J Vet Med B Infect Dis Vet Public Health. 2004;51:199–201. [DOI] [PubMed]

25.

Ganti RS, Chakraborty AK. Mechanisms underlying vaccination protocols that may optimally elicit broadly neutralizing antibodies against highly mutable pathogens. Phys Rev E. 2021;103:052408. [DOI] [PubMed]

26.

Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020;369:731–6. [DOI] [PubMed] [PMC]

27.

Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021;27:106–14. [DOI] [PubMed]